Foundayo: the second GLP-1 pill, and the first without the fasting rule
Four months after Novo's Wegovy pill, Lilly answered with orforglipron — a small-molecule GLP-1 you can take with food. The differences are bigger than the marketing suggests.
Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1 receptor agonist, approved by the FDA in April 2026 for chronic weight management. Unlike oral semaglutide, it is a non-peptide small molecule, so it needs no fasting window and no water-and-wait ritual. CVS Caremark lifted its new-to-market block on June 1, 2026, and eligible commercial patients can access it for as little as $25 per month; self-pay pricing starts around $149 through LillyDirect.
- What orforglipron is, and why the chemistry matters: Every GLP-1 you have heard of until now — semaglutide, tirzepatide, liraglutide — is a peptide: a chain of amino acids that stomach enzymes destroy....
- The trial evidence, without the spin: In Lilly's Phase III ATTAIN program in adults with obesity or overweight without diabetes, orforglipron at the highest dose produced average weight....
- Launch pricing and channels: Foundayo launched through LillyDirect with starter-dose self-pay pricing around $149 per month — matching the anchor price Novo set for the Wegovy ....
- Foundayo vs the Wegovy pill vs injections: Against oral semaglutide, Foundayo's edge is entirely behavioral: no fasting protocol means fewer missed-dose failure modes, and adherence drives r....
- No, there is no legal compounded orforglipron: Expect gray-market sellers to offer “research-grade orforglipron” powders and capsules.
What orforglipron is, and why the chemistry matters
Every GLP-1 you have heard of until now — semaglutide, tirzepatide, liraglutide — is a peptide: a chain of amino acids that stomach enzymes destroy, which is why they are injected, and why oral semaglutide needs an absorption enhancer plus a strict empty-stomach protocol. Orforglipron is different in kind: a small-molecule, non-peptide GLP-1 receptor agonist that survives digestion on its own.
The practical consequences are the whole story. No refrigeration, no needles, no fasting window, no 30-minute wait, no restrictions on taking it alongside other morning medications. It is also cheaper to manufacture at scale than peptide products, which is why analysts expect oral small molecules to anchor the value tier of this class over time.
| Product | Molecule | Food restriction | Self-pay start | Maintenance cash |
|---|---|---|---|---|
| Foundayo | Orforglipron (small molecule) | None | ~$149/mo | Tiered above starter |
| Wegovy pill | Semaglutide 25 mg (peptide) | Empty stomach + 30-min wait | $149/mo | ~$299/mo |
| Rybelsus | Semaglutide ≤14 mg (peptide) | Empty stomach + 30-min wait | Insurance-dependent | T2D indication |
| Compounded ODT sema/tirz | Peptide, unproven route | Varies | $99–$299/mo | No trial evidence |
The trial evidence, without the spin
In Lilly's Phase III ATTAIN program in adults with obesity or overweight without diabetes, orforglipron at the highest dose produced average weight loss in the low-to-mid teens as a percentage of body weight over roughly 72 weeks — meaningfully better than placebo and broadly comparable to oral semaglutide's treatment-policy results, but below injectable tirzepatide's 20-plus percent averages.
Side effects are class-typical and dose-dependent: nausea, vomiting, constipation and diarrhea concentrated during dose escalation, with discontinuation rates in the range seen across GLP-1 trials. The honest summary: orforglipron trades some peak efficacy against injectable tirzepatide for radical convenience. For a large group of patients — needle-averse, routine-sensitive, or simply starting treatment — that is a rational trade.
Launch pricing and channels
Foundayo launched through LillyDirect with starter-dose self-pay pricing around $149 per month — matching the anchor price Novo set for the Wegovy pill in January — with higher maintenance doses tiered above that, consistent with how both manufacturers now price orals. Commercially insured patients on plans that cover it may pay as little as $25 per month under Lilly's savings program.
The formulary picture moved fast. CVS Caremark removed its new-to-market block on June 1, 2026, adding Foundayo where plan sponsors approve coverage, and from October 1 it will sit alongside Zepbound and Wegovy in Caremark's expanded GLP-1 tier. Express Scripts and Optum Rx maintain their own review timelines; as always, the plan-sponsor opt-out for weight-loss drugs is the gate that matters.
Foundayo vs the Wegovy pill vs injections
Against oral semaglutide, Foundayo's edge is entirely behavioral: no fasting protocol means fewer missed-dose failure modes, and adherence drives real-world results more than trial deltas do. Against injectables, both pills concede peak efficacy — if you tolerate a weekly injection and want maximum weight loss, tirzepatide remains the evidence leader in head-to-head and cross-trial data.
Price-wise the two pills launched deliberately close: $149 starter tiers, roughly $299 maintenance ranges, and $25 insured copays on covered plans. The decision between them is less about cost than about the fasting rule and about which manufacturer's channel — NovoCare or LillyDirect — your plan or telehealth provider is integrated with.
No, there is no legal compounded orforglipron
Expect gray-market sellers to offer “research-grade orforglipron” powders and capsules. Two facts to hold onto. First, orforglipron is not on any FDA shortage list, and post-2025 enforcement makes routine compounding of copies of available drugs unlawful outside narrow personalization exceptions — a small-molecule pill offers no plausible personalization rationale.
Second, unlike compounded semaglutide from state-licensed pharmacies, powder sold online as orforglipron has no pharmacy chain of custody at all. Our peptide-market testing coverage applies with full force here: no verification, no potency assurance, and real counterfeit risk. There is no verified-price row for this product in our database and there will not be one.
What Foundayo does to the market
A second oral entrant does three things. It normalizes pill-first GLP-1 treatment for new patients, which expands the total market rather than cannibalizing injections. It gives PBMs a competitive oral tier to negotiate — the CVS announcement explicitly credited manufacturer competition for the expanded formulary. And it puts a ceiling on what compounded oral products can charge, because an FDA-approved pill at $149 makes unproven ODT formulations at similar prices unsellable.
For our pricing database, Foundayo enters the brand oral tier alongside the Wegovy pill; we track both against the compounded injectable floor, which remains the lowest verified monthly cost in the class.
Frequently asked questions
Is Foundayo stronger than the Wegovy pill?
Cross-trial comparisons put their average weight loss in a similar band, with injectable tirzepatide above both. Foundayo's real advantage is taking it without fasting rules, which helps adherence — often the bigger driver of real-world results.
Can I get compounded orforglipron cheaper?
No legal version exists. Orforglipron is not in shortage, and compounded copies of available drugs are unlawful outside narrow exceptions. Powders sold online as orforglipron have no pharmacy verification and should be treated as counterfeit-risk products.
Does insurance cover it?
Where plan sponsors cover weight-loss GLP-1s: CVS Caremark added it June 1, 2026, and Lilly's savings program brings eligible commercial copays to about $25. Confirm your specific plan; the employer opt-out still applies.